PT - JOURNAL ARTICLE AU - Jonas C. Schupp AU - Sara Khanal AU - Jose L. Gomez AU - Maor Sauler AU - Taylor S. Adams AU - Geoffrey L. Chupp AU - Xiting Yan AU - Sergio Poli AU - Ruth R. Montgomery AU - Ivan O. Rosas AU - Charles S. Dela Cruz AU - Emanuela M. Bruscia AU - Marie E. Egan AU - Naftali Kaminski AU - Clemente J. Britto TI - Single Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis AID - 10.1101/2020.03.06.20032292 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.06.20032292 4099 - http://medrxiv.org/content/early/2020/03/10/2020.03.06.20032292.short 4100 - http://medrxiv.org/content/early/2020/03/10/2020.03.06.20032292.full AB - Cystic fibrosis (CF) is a life-shortening multisystem hereditary disease caused by abnormal chloride transport. CF lung disease is driven by innate immune dysfunction that perpetuates inflammation. The airways provide a window into CF pathogenesis, as immune cells display exaggerated inflammatory responses and impaired phagocytic function, contributing to tissue injury. In order to define the transcriptional profile of this airway immune dysfunction, we performed the first single-cell transcriptome characterization of CF sputum. We show that the airway immune cell repertoire shifted from alveolar macrophages in HC to a predominance of recruited monocytes and neutrophils in CF. Recruited lung mononuclear phagocytes were abundant in CF, separated into three archetypes: activated monocytes, monocyte-derived macrophages, and heat-shock activated monocytes. Neutrophils were most prevalent in CF, with a dominant immature proinflammatory archetype. While CF monocytes exhibited proinflammatory features, both monocytes and neutrophils showed transcriptional evidence of abnormal phagocytic and cell-survival programs. Our findings offer an opportunity to understand subject-specific immune dysfunction and its contribution to divergent clinical courses in CF. As we progress towards personalized applications of therapeutic and genomic developments, we hope this inflammation profiling approach will enable further discoveries that change the natural history of CF lung disease.Competing Interest StatementNK reports the following disclosures: Personal fees from Boehringer Ingelheim, Third Rock, Pliant, NuMedii, Indaloo, Theravance, LifeMax, Three Lake Partners, outside the submitted work; In addition, NK has a patent for New Therapies in Pulmonary Fibrosis with royalties paid to Biotech, and a patent Peripheral Blood Gene Expression issued, Served as Deputy Editor of Thorax, BMJ. And Chair of TLP scientific advisory committee. All other authors report nothing to disclose.Funding StatementThis work was supported by The National Institutes of Health & National Heart, Lung, and Blood Institute (USA) through grants NIH T32-HL007778 and K01-HL125514-01 (CB); the Cystic Fibrosis Foundation through its Fifth Year Clinical Fellowship Award (CB); the American Thoracic Society Foundation’s Unrestricted Research Award (CB); NIH U01 HL145567 and R01 HL127349 (NK); and DoD W81XWH-19-1-0131 (JCS).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data was deposited on the gene expression omnibus (GEO) under accession number GSE145360. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145360